A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge

Yfat Yahalom-Ronen; Hadas Tamir; Sharon Melamed; Boaz Politi; Ohad Shifman; Hagit Achdout; Einat B. Vitner; Ofir Israeli; Elad Milrot; Dana Stein; Inbar Cohen-Gihon; Shlomi Lazar; Hila Gutman; Itai Glinert; Lilach Cherry; Yaron Vagima; Shirley Lazar; Shay Weiss; Amir Ben-Shmuel; Roy Avraham; Reut Puni; Edith Lupu; Elad Bar-David; Assa Sittner; Noam Erez; Ran Zichel; Emanuelle Mamroud; Ohad Mazor; Haim Levy; Orly Laskar; Shmuel Yitzhaki; Shmuel C. Shapira; Anat Zvi; Adi Beth-Din; Nir Paran; Tomer Israely

doi:10.1038/s41467-020-20228-7

A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge

Yfat Yahalom-Ronen, Hadas Tamir, Sharon Melamed, Boaz Politi, Ohad Shifman, Hagit Achdout, Einat B. Vitner, Ofir Israeli, Elad Milrot, Dana Stein, Inbar Cohen-Gihon, Shlomi Lazar, Hila Gutman, Itai Glinert, Lilach Cherry, Yaron Vagima, Shirley Lazar, Shay Weiss, Amir Ben-Shmuel, Roy AvrahamReut Puni, Edith Lupu, Elad Bar-David, Assa Sittner, Noam Erez, Ran Zichel, Emanuelle Mamroud, Ohad Mazor, Haim Levy, Orly Laskar, Shmuel Yitzhaki, Shmuel C. Shapira, Anat Zvi, Adi Beth-Din, Nir Paran, Tomer Israely

Research output: Contribution to journal › Article › peer-review

174 Scopus citations

Abstract

The COVID-19 pandemic caused by SARS-CoV-2 imposes an urgent need for rapid development of an efficient and cost-effective vaccine, suitable for mass immunization. Here, we show the development of a replication competent recombinant VSV-∆G-spike vaccine, in which the glycoprotein of VSV is replaced by the spike protein of SARS-CoV-2. In-vitro characterization of this vaccine indicates the expression and presentation of the spike protein on the viral membrane with antigenic similarity to SARS-CoV-2. A golden Syrian hamster in-vivo model for COVID-19 is implemented. We show that a single-dose vaccination results in a rapid and potent induction of SARS-CoV-2 neutralizing antibodies. Importantly, vaccination protects hamsters against SARS-CoV-2 challenge, as demonstrated by the abrogation of body weight loss, and alleviation of the extensive tissue damage and viral loads in lungs and nasal turbinates. Taken together, we suggest the recombinant VSV-∆G-spike as a safe, efficacious and protective vaccine against SARS-CoV-2.

Original language	English
Article number	6402
Journal	Nature Communications
Volume	11
Issue number	1
DOIs	https://doi.org/10.1038/s41467-020-20228-7
State	Published - 1 Dec 2020
Externally published	Yes

ASJC Scopus subject areas

General Chemistry
General Biochemistry, Genetics and Molecular Biology
General Physics and Astronomy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41467-020-20228-7

Cite this

Yahalom-Ronen, Y., Tamir, H., Melamed, S., Politi, B., Shifman, O., Achdout, H., Vitner, E. B., Israeli, O., Milrot, E., Stein, D., Cohen-Gihon, I., Lazar, S., Gutman, H., Glinert, I., Cherry, L., Vagima, Y., Lazar, S., Weiss, S., Ben-Shmuel, A., ... Israely, T. (2020). A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge. Nature Communications, 11(1), Article 6402. https://doi.org/10.1038/s41467-020-20228-7

@article{1331a40fb92946de8dd5201dc84294bd,

title = "A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge",

abstract = "The COVID-19 pandemic caused by SARS-CoV-2 imposes an urgent need for rapid development of an efficient and cost-effective vaccine, suitable for mass immunization. Here, we show the development of a replication competent recombinant VSV-∆G-spike vaccine, in which the glycoprotein of VSV is replaced by the spike protein of SARS-CoV-2. In-vitro characterization of this vaccine indicates the expression and presentation of the spike protein on the viral membrane with antigenic similarity to SARS-CoV-2. A golden Syrian hamster in-vivo model for COVID-19 is implemented. We show that a single-dose vaccination results in a rapid and potent induction of SARS-CoV-2 neutralizing antibodies. Importantly, vaccination protects hamsters against SARS-CoV-2 challenge, as demonstrated by the abrogation of body weight loss, and alleviation of the extensive tissue damage and viral loads in lungs and nasal turbinates. Taken together, we suggest the recombinant VSV-∆G-spike as a safe, efficacious and protective vaccine against SARS-CoV-2.",

author = "Yfat Yahalom-Ronen and Hadas Tamir and Sharon Melamed and Boaz Politi and Ohad Shifman and Hagit Achdout and Vitner, \{Einat B.\} and Ofir Israeli and Elad Milrot and Dana Stein and Inbar Cohen-Gihon and Shlomi Lazar and Hila Gutman and Itai Glinert and Lilach Cherry and Yaron Vagima and Shirley Lazar and Shay Weiss and Amir Ben-Shmuel and Roy Avraham and Reut Puni and Edith Lupu and Elad Bar-David and Assa Sittner and Noam Erez and Ran Zichel and Emanuelle Mamroud and Ohad Mazor and Haim Levy and Orly Laskar and Shmuel Yitzhaki and Shapira, \{Shmuel C.\} and Anat Zvi and Adi Beth-Din and Nir Paran and Tomer Israely",

note = "Publisher Copyright: {\textcopyright} 2020, The Author(s).",

year = "2020",

month = dec,

day = "1",

doi = "10.1038/s41467-020-20228-7",

language = "English",

volume = "11",

journal = "Nature Communications",

issn = "2041-1723",

publisher = "Nature Research",

number = "1",

}

Yahalom-Ronen, Y, Tamir, H, Melamed, S, Politi, B, Shifman, O, Achdout, H, Vitner, EB, Israeli, O, Milrot, E, Stein, D, Cohen-Gihon, I, Lazar, S, Gutman, H, Glinert, I, Cherry, L, Vagima, Y, Lazar, S, Weiss, S, Ben-Shmuel, A, Avraham, R, Puni, R, Lupu, E, Bar-David, E, Sittner, A, Erez, N, Zichel, R, Mamroud, E, Mazor, O, Levy, H, Laskar, O, Yitzhaki, S, Shapira, SC, Zvi, A, Beth-Din, A, Paran, N & Israely, T 2020, 'A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge', Nature Communications, vol. 11, no. 1, 6402. https://doi.org/10.1038/s41467-020-20228-7

TY - JOUR

T1 - A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge

AU - Yahalom-Ronen, Yfat

AU - Tamir, Hadas

AU - Melamed, Sharon

AU - Politi, Boaz

AU - Shifman, Ohad

AU - Achdout, Hagit

AU - Vitner, Einat B.

AU - Israeli, Ofir

AU - Milrot, Elad

AU - Stein, Dana

AU - Cohen-Gihon, Inbar

AU - Lazar, Shlomi

AU - Gutman, Hila

AU - Glinert, Itai

AU - Cherry, Lilach

AU - Vagima, Yaron

AU - Lazar, Shirley

AU - Weiss, Shay

AU - Ben-Shmuel, Amir

AU - Avraham, Roy

AU - Puni, Reut

AU - Lupu, Edith

AU - Bar-David, Elad

AU - Sittner, Assa

AU - Erez, Noam

AU - Zichel, Ran

AU - Mamroud, Emanuelle

AU - Mazor, Ohad

AU - Levy, Haim

AU - Laskar, Orly

AU - Yitzhaki, Shmuel

AU - Shapira, Shmuel C.

AU - Zvi, Anat

AU - Beth-Din, Adi

AU - Paran, Nir

AU - Israely, Tomer

PY - 2020/12/1

Y1 - 2020/12/1

N2 - The COVID-19 pandemic caused by SARS-CoV-2 imposes an urgent need for rapid development of an efficient and cost-effective vaccine, suitable for mass immunization. Here, we show the development of a replication competent recombinant VSV-∆G-spike vaccine, in which the glycoprotein of VSV is replaced by the spike protein of SARS-CoV-2. In-vitro characterization of this vaccine indicates the expression and presentation of the spike protein on the viral membrane with antigenic similarity to SARS-CoV-2. A golden Syrian hamster in-vivo model for COVID-19 is implemented. We show that a single-dose vaccination results in a rapid and potent induction of SARS-CoV-2 neutralizing antibodies. Importantly, vaccination protects hamsters against SARS-CoV-2 challenge, as demonstrated by the abrogation of body weight loss, and alleviation of the extensive tissue damage and viral loads in lungs and nasal turbinates. Taken together, we suggest the recombinant VSV-∆G-spike as a safe, efficacious and protective vaccine against SARS-CoV-2.

AB - The COVID-19 pandemic caused by SARS-CoV-2 imposes an urgent need for rapid development of an efficient and cost-effective vaccine, suitable for mass immunization. Here, we show the development of a replication competent recombinant VSV-∆G-spike vaccine, in which the glycoprotein of VSV is replaced by the spike protein of SARS-CoV-2. In-vitro characterization of this vaccine indicates the expression and presentation of the spike protein on the viral membrane with antigenic similarity to SARS-CoV-2. A golden Syrian hamster in-vivo model for COVID-19 is implemented. We show that a single-dose vaccination results in a rapid and potent induction of SARS-CoV-2 neutralizing antibodies. Importantly, vaccination protects hamsters against SARS-CoV-2 challenge, as demonstrated by the abrogation of body weight loss, and alleviation of the extensive tissue damage and viral loads in lungs and nasal turbinates. Taken together, we suggest the recombinant VSV-∆G-spike as a safe, efficacious and protective vaccine against SARS-CoV-2.

UR - https://www.scopus.com/pages/publications/85097621373

U2 - 10.1038/s41467-020-20228-7

DO - 10.1038/s41467-020-20228-7

M3 - Article

C2 - 33328475

AN - SCOPUS:85097621373

SN - 2041-1723

VL - 11

JO - Nature Communications

JF - Nature Communications

IS - 1

M1 - 6402

ER -

A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this